- Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma2021 | Faculty of Medicine in Hradec Králové
- Treatment of HER2-positive breast cancer in 20202020 | First Faculty of Medicine
- A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy2018 | First Faculty of Medicine
- Treatment of Relapsed/Refractory Hodgkin Lymphoma: Real-World Data from the Czech Republic and Slovakia2019 | Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline?2023 | First Faculty of Medicine
- Targeted Drug Delivery and Theranostic Strategies in Malignant Lymphomas2022 | First Faculty of Medicine
- Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma2022 | First Faculty of Medicine
- Trastuzumab deruxtecan: strong player in the field of metastatic HER2 positive breast cancer2022 | First Faculty of Medicine
- Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study2021 | First Faculty of Medicine
- Different Reaction Specificities of F420H2-Dependent Reductases Facilitate Pyrrolobenzodiazepines and Lincomycin To Fit Their Biological Targets2020 | Faculty of Science
- Biological Therapy of Hematologic Malignancies: Toward a Chemotherapy-free Era2019 | First Faculty of Medicine
- Trastuzumab deruxtecan as standard of care for second-line treatment of metastatic HER2-positive breast cancer2023 | First Faculty of Medicine
- Advancements in the treatment of adult acute lymphoblastic leukaemia2015 | Publication without faculty affiliation
- Sacituzumab govitecan2022 | First Faculty of Medicine
- Sacituzumab govitecan in the treatment of triple negative breast cancer2023 | First Faculty of Medicine
- Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Management and Emerging Treatment Options2022 | First Faculty of Medicine
- Hodgkin lymphoma - hendless story Hodgkin lymphoma - endless story2019 | Third Faculty of Medicine
- A Phase I study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)2021 | Second Faculty of Medicine
- Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study2023 | First Faculty of Medicine